Pacgen Life Science Corporation Reports Earnings Results for the Third Quarter Ended December 31, 2019

Pacgen Life Science Corporation, formerly Pacgen Biopharmaceuticals Corporation, is a life sciences company focused on the commercialization of life sciences products and services. The Company has a worldwide license to develop and commercialize an antifungal called P113 (also called PAC-113). It has sublicensed its PAC-113 right to General Biologicals Corporation (GBC), which offers non-prescription over-the-counter (OTC) products containing PAC-113 in Taiwan. P113 is a 12 amino-acid antimicrobial peptide derived from a histatin protein found in saliva. Its P113 is used for the treatment of various oral conditions, as well as vaginal, dermatological and ophthalmic conditions. GBC offers products, such as cosmetic skin-care products, oral hygiene products and intimate hygiene products. The oral healthcare product includes Mr.&Mrs.O. It has conducted a Phase IIb dose-ranging clinical trial for PAC-113. Its oral health and woman health products are in the commercialization stage.